Homeopathy in advanced malignant tumors

Prospective, randomized, controlled, open-label study evaluating quality of life in patients with advanced malignant tumors with and without “add-on” homeopathy - HIC

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-000739-97-AT

Enrollment

600

Registered

2011-04-19

Start date

2011-05-05

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Homeopathic remedies as add on therapie in cancer

Interventions

Trade Name: Homeopathic remedies Product Name: Homeopathic remedies Product Code: Homeopathic remedies Pharmaceutical Form: Other descriptive name: homeopathic remedies

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Diagnosis of glioblastoma IV, non small cell lung carcinoma IV and metastasized sarcoma within the last 8 weeks. • Patients aged over 18 years • signed informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: • Pregnancy • intake of homeopathic remedies except the prescribed ones; • refusal of intake of the prescribed homeopathic remedies

Design outcomes

Primary

Measure	Time frame
Main Objective: Reveal and describe the difference in Qol and SWB, in patient groups receiving standard treatment and “add on” homeopathic treatment. The null hypothesis is that “add-on” homeopathic treatment does not create a benefit for cancer patients with regard to QoL and SWB.;Secondary Objective: Reveal and describe the difference survival time, in patient groups receiving standard treatment and “add on” homeopathic treatment. The null hypothesis is that “add-on” homeopathic treatment does not create a benefit for cancer patients with regard to survival.;Primary end point(s): QoL and subjective well-being (questionnaires);Timepoint(s) of evaluation of this end point: 2 to 3 month	—

Measure

Time frame

Main Objective: Reveal and describe the difference in Qol and SWB, in patient groups receiving standard treatment and “add on” homeopathic treatment. The null hypothesis is that “add-on” homeopathic treatment does not create a benefit for cancer patients with regard to QoL and SWB.;Secondary Objective: Reveal and describe the difference survival time, in patient groups receiving standard treatment and “add on” homeopathic treatment. The null hypothesis is that “add-on” homeopathic treatment does not create a benefit for cancer patients with regard to survival.;Primary end point(s): QoL and subjective well-being (questionnaires);Timepoint(s) of evaluation of this end point: 2 to 3 month

—

Secondary

Measure	Time frame
Secondary end point(s): • To assess efficacy of homeopathy on survival in patients with advanced malignant tumors with and without “add-on” homeopathy;Timepoint(s) of evaluation of this end point: 2 to 3 month	—

Countries

Austria

Contacts

Public ContactProf. Frass

Med. Univ. Wien

michael.frass@meduniwien.ac.at00431404004506

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026